Dr. Gulam A. Manji
Claim this profileColumbia University
Area of expertise
Pancreatic Cancer
Gulam A. Manji has run 4 trials for Pancreatic Cancer. Some of their research focus areas include:
Cervical Adenocarcinoma
Gulam A. Manji has run 2 trials for Cervical Adenocarcinoma. Some of their research focus areas include:
Affiliated Hospitals
Columbia University
Columbia University Irving Medical Center
Clinical Trials Gulam A. Manji is currently running
CA-4948 + Chemotherapy
for Pancreatic Cancer
This phase I trial tests the safety, side effects, and best dose of emavusertib (CA-4948) in combination with gemcitabine and nab-paclitaxel in treating patients with pancreatic ductal adenocarcinoma that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable). CA-4948 is in a class of medications called kinase inhibitors. It works by blocking the action of abnormal proteins called interleukin-1 receptor-associated kinase 4 (IRAK4) and FMS-like tyrosine kinase 3 (FLT3) that signal cells to multiply. This may help keep cancer cells from growing. The usual approach for patients with pancreatic ductal adenocarcinoma is treatment with chemotherapy drugs gemcitabine and nab-paclitaxel. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill cancer cells. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. Giving CA-4948 in combination with gemcitabine and nab-paclitaxel may shrink or stabilize metastatic or unresectable pancreatic ductal adenocarcinoma.
Recruiting
1 award
Phase 1
20 criteria
Combination Therapy
for Pancreatic Cancer
The purpose of this study is to combine standard radiation therapy with drugs that encourages the body's immune system against cancer cells and simultaneously adding drugs which also target the pathway that the tumor uses to evade the immune system (CD73 and A2a/b). The study hopes that these drugs will work in concert with radiation therapy to kill cancer cells. The specific goal of this study is to ensure that treatment with zimberelimab and stereotactic body radiation therapy (SBRT) alone or in combination with quemliclustat (a drug which blocks CD73), with or without etrumadenant (a drug which blocks the A2a/b) given before surgery is safe and if it can further increase the immune response against the tumor.
Recruiting
1 award
Phase 2
11 criteria
More about Gulam A. Manji
Clinical Trial Related
8 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Gulam A. Manji has experience with
- Gemcitabine
- Zimberelimab
- Cemiplimab
- Motixafortide
- Nab Paclitaxel
- Etrumadenant
Breakdown of trials Gulam A. Manji has run
Pancreatic Cancer
Cervical Adenocarcinoma
Pancreatic Adenocarcinoma
Adenocarcinoma
Peripheral Nerve Sheath Tumor
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Gulam A. Manji specialize in?
Gulam A. Manji focuses on Pancreatic Cancer and Cervical Adenocarcinoma. In particular, much of their work with Pancreatic Cancer has involved Stage IV patients, or patients who are Stage III.
Is Gulam A. Manji currently recruiting for clinical trials?
Yes, Gulam A. Manji is currently recruiting for 3 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Gulam A. Manji has studied deeply?
Yes, Gulam A. Manji has studied treatments such as Gemcitabine, Zimberelimab, Cemiplimab.
What is the best way to schedule an appointment with Gulam A. Manji?
Apply for one of the trials that Gulam A. Manji is conducting.
What is the office address of Gulam A. Manji?
The office of Gulam A. Manji is located at: Columbia University, New York, New York 10032 United States. This is the address for their practice at the Columbia University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.